Recent studies indicate that dementia diagnoses in the U.S. could double over the next 40 years, surpassing one million annually. This surge is expected to significantly increase the demand for nuclear imaging, particularly PET scans, which play a crucial role in managing cognitive disorders. Experts emphasize the importance of both amyloid and tau imaging in assessing Alzheimer's disease and guiding patient treatment. Updated criteria for these imaging techniques have been established, reflecting advancements in Alzheimer’s research and therapies. Additionally, the Centers for Medicare and Medicaid Services recently lifted restrictions on coverage for PET scans related to dementia care, improving patient access. Experts suggest that the integration of artificial intelligence in imaging and the healthcare industry is key to addressing challenges like declining reimbursement rates and improving efficiency in patient care.
Mon, 20 Jan 2025 21:35:00 GMT | Health Imaging